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ABSTRACT
Background: A controlled-release (CR) form of diclofenac-potassium has
been developed, which delivers 100 mg over the course of 24 hours. This for-
mulation is administered QD and provides steady plasmatic levels of the drug.
Objective: The aim of this study was to compare the effectiveness and tol-
erability of CR diclofenac-potassium versus the immediate-release (IR) formula-
tion, when used for treatment of pain in patients with knee osteoarthritis.
Methods: This prospective, randomized, double-blind, comparative, multi-
center, parallel-group study was conducted in male and female patients who
had been previously diagnosed with knee osteoarthritis. Inclusion criteria
included knee joint pain and ≥3 of the following: age >50 years, morning rigidity
lasting <30 minutes, crackling in the joint, pain with applied pressure to the
bones, bone hypertrophy, absence of articular heat, and a radiology status of 
I to III on the Kellgren-Lawrence scale. Patients were randomly divided into 1 of
2 equal-sized groups: 1 group received diclofenac-potassium IR 50 mg BID for 
30 days and 1 group received diclofenac-potassium CR 100 mg QD for 30 days.
Patients were assessed at baseline and again at 15 and 30 days after initiation of
treatment with a physical examination, pain measurement via 100-mm visual
analog scale (VAS), and Western Ontario McMaster (WOMAC) osteoarthritis
index questionnaire. Adverse events (AEs) were assessed by direct interroga-
tion, hematology controls, blood chemistry, hepatic tests, coagulation tests,
and urine tests performed on patients before treatment initiation and on day 30.
Results: Sixty-five patients were screened and 62 patients (mean [SD] age, 
61.8 [8.9] years; mean [SD] weight, 71.3 [12.4] kg; female sex, 55 [88.9%]) were
included in the study; each study group had 31 patients. After 30 days, both prod-
ucts were equally effective in relieving pain, as measured by VAS (IR, 17.3 vs CR,
21.6; P = NS), and changes in the WOMAC score (IR, 14.5 vs CR, 19.2; P = NS).
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Significantly more patients in the IR group reported feeling better after 30 days
than in the CR group (94% vs 76%; P = 0.002) and, according to the physician’s
opinion, significantly more patients treated with diclofenac-potassium IR felt bet-
ter (97% vs 83%; P = 0.03). Significantly more patients in the IR group required res-
cue medication than those in the CR group (36% vs 26%; P = 0.03). In the CR group,
7 patients experienced AEs: 6 were gastrointestinal (ie, pyrosis, epigastralgia,
dyspepsia) and 1 patient experienced increased arterial pressure. One patient
from this group discontinued treatment due to a lack of efficacy. In the IR group,
6 patients experienced AEs (ie, tachycardia, epigastralgia, and pyrosis). One
patient discontinued because of AEs, and 3 withdrew due to a lack of efficacy.
Conclusion: Based on the results from this small study in a Venezuelan pop-
ulation, both IR and CR formulations of diclofenac-potassium have similar effec-
tiveness and tolerability profiles. (Curr Ther Res Clin Exp. 2007;68:82–93) Copyright
© 2007 Excerpta Medica, Inc.
Key words: diclofenac-potassium, immediate release, controlled release,
osteoarthritis.
INTRODUCTION
Considered the most common articular illness, osteoarthritis is one of the lead-
ing health problems among middle-aged and elderly people.1 Clinically, this ill-
ness is characterized by pain and physical dysfunction. It can progress to mus-
cular atrophy contractures and finally articular deformity. Osteoarthritis is a
chronic and degenerative process of the joints, with progressive loss of articu-
lar cartilage and, later, the formation of osteophytes.2 Cartilage degeneration
and inflammation of the synovia work together, causing pain, inflammation, and
intra-articular hemorrhage.3
Osteoarthritis is the most common rheumatoid disease and can affect up to
85% of the population of those aged ≥70 years and 20% of the general popula-
tion in the United States.4 In people aged ≥40 years, the rate of incidence
increases rapidly and it occurs more frequently in women than in men.
Osteoarthritis can attack any joint, but is more frequently found in the
hands, feet, knees, hip, and spine; it is less common in wrists, elbows, shoulders,
and ankles.2 There are many factors responsible for secondary osteoarthritis,
such as genetic susceptibility, obesity, female sex, and joint hypermobility.5 In
all the populations studied, the main risk factor is age.4,5 The physiopathology
of this illness is still not clear and, for this reason, its treatment and any attempt
to slow down its progression are more speculative than truly scientific in
nature. In 2000, the American College of Rheumatology (ACR) and the European
League of Associations of Rheumatology both published recommendations for
the treatment of lower limb osteoarthritis, based on available evidence obtained
from the latest guideline revisions and meta-analyses.6–8
Acetaminophen has been one of the most frequently used, well tolerated,
and relatively safe drugs for patients suffering from moderate pain. However,
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high doses might cause adverse gastrointestinal effects, similar to those pro-
duced by NSAIDs.9–12 Studies have indicated that NSAIDs are more effective than
acetaminophen in the treatment of pain in patients suffering from osteoarthri-
tis.10–15 Diclofenac-potassium, widely used in the treatment of osteoarthritis in
doses of 100 to 150 mg daily, is a derivative of phenylacetic acid and has excel-
lent antipyretic, analgesic, and anti-inflammatory properties.16–19
After receiving an oral dose of 50 mg of diclofenac-potassium, plasmatic levels
appeared in patients within 10 minutes, and absorption was essentially complete,
with an AUC proportional to the dose administered.19 A 50-mg dose of diclofenac-
potassium administered in tablet form produces an average plasmatic peak of 
3.8 µmol/L within 20 to 60 minutes of the drug’s administration.16–19
Diclofenac-potassium features an important first hepatic step; with a sys-
temic bioavailability of ~50%, its absorption is not affected by food ingestion,
and repeated administration TID for 8 consecutive days has not been reported
to produce accumulation phenomena.19 It binds to plasmatic proteins and
reaches the synovial liquid, where Tmax occurs 2 to 4 hours after plasmatic Tmax,
and Cmax exceeds the plasmatic Cmax within 4 to 6 hours after administration. The
elimination t1/2 of diclofenac-potassium from joints is higher than from plasma.
Diclofenac-potassium is metabolized and converted into glucuronide deriva-
tives.19 Mean (SD) plasmatic clearance is 263 (56) mL/min, with a terminal plas-
matic t1/2 of 1.8 hours after oral administration.
Some mechanisms governing the antipyretic, analgesic, and anti-inflammatory
effects of diclofenac-potassium are as follows: inhibition of cyclooxygenase, arachi-
donic acid cascade, and phosphodiesterase central modulation.16–18 Improve-
ment in galenic formulation techniques has allowed for the development of
several formulations which offer advantages over more conventional forms
while maintaining their proven effectiveness. An example of this is the controlled-
release (CR) format, which allows for a less frequent administration.
In Venezuela, a CR formulation of diclofenac-potassium* has been developed
that delivers 100 mg over the course of 24 hours and is administered QD. It is a
matrix-type tablet which, by the effect of its excipients, forms a hydrophilic
matrix with a delaying effect on the release of diclofenac-potassium. The release
rate of diclofenac-potassium from the tablet’s matrix is determined by the abil-
ity of the gastrointestinal fluids to penetrate the tablet and the formation in the
gastrointestinal tract of a gelatin-like matrix which releases the active ingredi-
ent in a controlled way.
The CR formulation has been found to provide steady plasmatic levels for 
24 hours.20 A pharmacokinetic study performed on 12 healthy volunteers found
that after administration of diclofenac-potassium 100 mg CR, a mean (SD) Cmax
of 736.8 (59.95) ng/mL was achieved with the first dose and 783.22 (86.04) ng/mL
with the third dose; a mean (SD) Tmax of 8.67 (4.12) hours was also observed
with the third dose.
*Trademark: Diklason AP® (Biocontrolled Laboratories C.A., Caracas, Venezuela).
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After the Cmax was reached, the mean (SD) plasma level decreased to 233.69
(47.8) ng/mL after 20 hours with the first dose and to 186.94 (44.7) ng/mL after
the third dose. The mean (SD) AUC of day 1 was 9681.83 (566.58) ng/mL  h–1 and
8127.87 ng/mL  h–1 on day 3. The lack of significant variation in AUC values
between day 1 and 3 indicated that there was no accumulation effect and the
plasma concentrations were maintained within the range reported in the litera-
ture as being effective (417–1312 ng/mL).20,21
The aim of this study was to compare the effectiveness and tolerability of CR
diclofenac-potassium versus the immediate-release (IR) formulation when used
for treatment of pain in patients with knee osteoarthritis.
PATIENTS AND METHODS
Study Design
This prospective, randomized, double-blind, comparative, multicenter, parallel-
group study was performed at 3 hospitals: Dr. José María Vargas Hospital,
Medical Center of Caracas, and Dr. Domingo Luciani Hospital, all of Caracas,
Venezuela. It was conducted in accordance with the principles of the
Declaration of Helsinki22 and the guidelines of Good Clinical Practice.23 Patients
were offered sufficient information about the purpose and scope of the study,
and were asked to provide written informed consent (previously reviewed and
approved by the institution’s ethics committee).
Inclusion and Exclusion Criteria
Male and female patients enrolled in this study had been previously diag-
nosed with knee osteoarthritis, according to ACR criteria24 (knee joint pain
with ≥3 of the following: age >50 years, morning rigidity lasting <30 minutes,
crackling in the joint, pain with applied pressure to the bones, bone hyper-
trophy, absence of articular heat) and had a radiology status of I to III on the
Kellgren-Lawrence scale.25
Patients were excluded for any of the following reasons: hypersensitivity to
NSAIDs; history of cerebrovascular events during the previous 2 years; hemor-
rhagic disorders, anticoagulation; pregnancy or lactation; asthma; serious con-
comitant illness (eg, liver, kidney, blood disease); patients with a prosthetic
knee or who had undergone other type of intra-articular surgery or had suffered
arthrocentesis in the 3 months before the study; diagnosis of fibromyalgia,
rheumatoid arthritis, ankylosing spondylitis, or gout; or active gastrointestinal
illness (eg, intestinal or gastric ulcer, Crohn’s disease, ulcerative colitis). Also
excluded were patients in whom the use of NSAIDs would be harmful or not rec-
ommended. Finally, patients were excluded if they, in the 8 weeks before study
initiation, had undergone treatment with steroids (administered intramuscu-
larly or intra-articularly) or hyaluronic acid.
Patients receiving treatment with analgesic medication, other than that being
tested, were subjected to a washout period of ≥5 days, depending on the medi-
cation they had been taking.
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None of the following drugs were allowed either 5 days before or during the
study: anticoagulants, hydantoin, oral antidiabetics, antimalarial agents, other
NSAIDs, immunosuppressive agents, central or peripheral analgesics, steroids,
muscle-relaxing agents, neuroleptics, and antidepressants. Use of acetamino-
phen was allowed as rescue medication.
Study Drug Administration
Patients were randomly assigned by aleatory table to 1 of 2 study groups: (1)
patients receiving PO diclofenac-potassium CR 100 mg QD; or (2) PO diclofenac-
potassium IR 50 mg BID (Novartis Laboratories, Caracas, Venezuela) for 30 days.
To blind patients to study drug selection, all patients received the same amount
of visually identical pills. All patients were required to self-administer 2 pills
daily; 1 between 7 and 9 AM, and 1 between 7 and 9 PM. Patients in the CR group
received 1 placebo pill and 1 active pill each day.
Patients were provided acetaminophen 500 mg as rescue medication. They
were required to record the number of pills administered, and the date and the
hour in which they ingested it.
Assessment of Effectiveness
The primary end point of this study was the effectiveness of CR diclofenac-
potassium 100 mg QD versus IR diclofenac-potassium 50 mg BID, in the relief of
pain as determined by a 100-mm visual analog scale (VAS) in patients with knee
osteoarthritis. The secondary end point was considered improvement of West-
ern Ontario McMaster (WOMAC)26 osteoarthritis index questionnaire scores (a
measure of pain, stiffness, and physical function) and impression of clinical
change, realized by patient and physician.
All patients were examined by a physician at treatment initiation (baseline,
visit 1), day 15 (visit 2), and day 30 (visit 3). Patients received their first dose at
baseline. They were then asked to record the moment when pain relief started
and when pain disappeared (if this happened) after the first dose, using the
VAS. During the first 3 days of treatment, a patient was required to measure his
or her pain level using the VAS, always before taking the next dose.
Patients returned after 15 and 30 days of starting medication to have a physi-
cal exam, pain measurement by VAS, and complete the WOMAC questionnaire.
Patients always returned to the same investigator for assessment. 
Tolerability Assessment
The adverse events (AEs) were assessed by direct interrogation, self-
reports, hematology controls, blood chemistry, hepatic tests, coagulation tests,
and urine tests performed on patients before treatment initiation and on day 30.
Statistical Analysis
A post hoc power analysis found that this study was able to detect a between-
group difference of 13 mm in the VAS scale, with an α error of 5% and a power
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of 90% (β error of 10%). The VAS scale results were analyzed by paired t test and
Wilcoxon signed rank test, within groups. WOMAC scores and results of clinical
change were analyzed by Wilcoxon signed rank test, within groups, and by
Mann-Whitney rank sum test between groups. Statistical significance was de-
fined as P < 0.05. All statistical analyses were performed using SPSS version 7.5
(SPSS Inc., Chicago, Illinois).
RESULTS
We screened 65 patients and a total of 62 patients (mean [SD] age, 61.8 [8.9] years;
mean [SD] weight, 71.3 [12.4] kg; female sex, 55 [88.9%]) were included in the
analysis. Patients were statistically similar in both groups with regard to age,
weight, height, sex, systolic and diastolic arterial pressures, history of pain
medication, and comorbidities (Table I). In the CR group, based on preliminary
WOMAC scores, osteoarthritis was perceived as being more severe.
In the CR group, 35.5% (11/31) reported no previous pathologies; 45.2%
(14/31) of the IR group. In both groups, the most frequently reported patho-
logic conditions were arterial hypertension (CR group, 48% vs IR group, 45%) and
type 2 diabetes mellitus (CR group, 13% vs IR group, 3%). Incidence of menopause
in women was reported by 73% of the CR group and 87% of the IR group.
The right knee was the most frequently affected in the IR group, while the CR
group reported both knees being equally affected. There was no difference in
radiology status between groups, and most patients were classified as anatomic
stage II.
Mean pain scores, as measured by the VAS, decreased significantly from the
first 24 hours in both the CR group (62.48–40.58; P = 0.03) and IR group
(61.39–38.28; P < 0.001). Overall decrease for the period of evaluation for each
group was not significantly different (CR group, 21.64 vs IR group, 17.29).
In the CR group, a statistically significant difference versus baseline in VAS
score was observed at 24, 48, and 60 hours, and 30 days after study initiation.
In the IR group, a statistically significant difference versus baseline in VAS score
was observed at 24 and 48 hours, and 15 and 30 days after study initiation.
There was no statistically significant between-group difference observed. VAS pain
measurement is shown in Table II and Figure 1.
WOMAC questionnaire scale scores improved significantly after the first 15 days
of treatment in both the CR group (39.67–23.73; P < 0.001) and the IR group
(36.71–14.50; P < 0.001). Improvement of mean scores continued to the study
end in both the CR group (19.24; P = 0.003) and the IR group (14.50; P = 0.001),
though there was no statistically significant between-group difference observed
(Table III and Figure 2).
Physician and Patient Opinion of Change
A significantly larger percentage of patients in the IR group reported feel-
ing better compared with those in the CR group (94% vs 76%, respectively; 
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Table I. Demographic characteristics of the patients at study initiation. Values are
presented as mean (SD), except where otherwise noted.
Diclofenac-Potassium Group*
Characteristic Overall CR (n = 31) IR (n = 31)
Age, y 61.8 (8.90) 60.87 (8.49) 62.68 (8.93)
Weight, kg 71.3 (12.40) 70.93 (13.30) 71.60 (11.66)
Height, m 1.57 (0.08) 1.57 (0.08) 1.57 (0.08)
Sex, no. (%)\
Female 55 (88.7) 27 (87.1) 28 (90.3)
Male 7 (11.3) 4 (12.9) 3 (9.4)
SAP, mm Hg 128.88 (13.98) 127.6 (13.03) 130.17 (15.03)
DAP, mm Hg 80.42 (7.50) 79.17 (7.55) 81.67 (7.35)
History of pain medication, no. (%) 54 (87.1) 27 (87.1) 27 (87.1)
Comorbidities, no. (%)
High blood pressure 29 (46.8) 15 (48.4) 14 (45.2)
Diabetes 5 (8.1) 4 (12.9) 1 (3.2)
CR = controlled release; IR = immediate release; SAP = systolic arterial pressure; DAP = diastolic arte-
rial pressure. 
*There were no statistically significant between-group differences.
Table II. Mean pain scores as measured by 100-mm visual analog scale reported by
patients receiving 100-mg diclofenac-potassium controlled release (CR) 
(n = 31) or 50-mg diclofenac-potassium immediate release (IR) (n = 31) for
the relief of pain associated with knee osteoarthritis.
Day Hour CR Group P* IR Group P* P†
Baseline 0 62.48 – 61.39 – 0.768
1 12 45.77 <0.001 41.79 <0.001 0.402
24 40.58 0.030 38.28 <0.001 0.611
2 12 41.03 0.858 38.72 0.829 0.638
24 37.80 0.055 34.93 0.006 0.551
3 12 32.35 0.001 31.48 0.113 0.824
24 31.42 0.256 29.72 0.057 0.684
15 12 33.24 0.563 24.18 0.100 0.043
30 24 21.64 0.056 17.29 0.045 0.334
*Versus baseline (Wilcoxon signed rank test).
†Between-group comparison (Mann-Whitney rank-sum test).
INTRO
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P = 0.002). According to the physician’s opinion, 97% of patients in the IR 
group had clinically improved compared with 83% of patients in the CR group
(P = 0.03).
Rescue Medication
Significantly more patients in the IR group (36%) required the use of rescue
medication compared with 26% of the CR group (P = 0.03).
Adverse Events
In the CR group, 7 patients experienced AEs: 6 were gastrointestinal (ie,
pyrosis, epigastralgia, dyspepsia) and 1 was due to increased arterial pres-
sure. One patient from this group discontinued treatment due to lack of effi-
cacy. In the IR group, 6 patients experienced AEs (ie, tachycardia, epigastral-
gia, and pyrosis). One patient discontinued because of AEs, and 3 because of
lack of efficacy.
No evidence of paraclinical alterations was observed with regard to hematolo-
gy, blood chemistry, coagulation parameters, and urine tests.
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Figure 1. Progression of mean visual analog scale (VAS) scores from treatment initia-
tion to study end in patients receiving 100-mg diclofenac-potassium con-
trolled release (CR) or 50-mg diclofenac-potassium immediate release (IR)
for the relief of pain associated with knee osteoarthritis.
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DISCUSSION
Knee osteoarthritis is a frequently occurring disease with a progressive evolu-
tion. It causes pain and has been related to a loss of quality of life in patients.27
According to the study by Chacon et al in a Venezuelan population with knee
osteoarthritis, quality of life is very much determined by the presence of
pain.27 In this disease, pain is the fundamental component; the adequate con-
trol of this symptom is a challenge for the physician. Although acetaminophen
had been the most widely used drug for the treatment of pain in osteoarthri-
tis,9 a recent study has shown that, statistically, NSAIDs are more often used,
with ethnic and racial variations.10 This study also found that NSAIDs were
more effective than acetaminophen for controlling pain associated with knee
osteoarthritis. These studies have also shown that the use of NSAIDs is as safe
as using acetaminophen.11
It is possible that the higher efficacy of NSAIDs can be explained by the inflam-
matory component of osteoarthritis. Inflammation present in osteoarthritis, on
the one hand, can stimulate angiogenesis, which in turn can facilitate not only
inflammation, but also promote chondrocyte hypertrophy and endochondral
ossification, producing articular changes detectable by radiology. However,
inflammation also sensitizes the nerves which contributes to an increase in
Table III. Evolution of Western Ontario McMaster (WOMAC) osteoarthritis index ques-
tionnaire scores in patients receiving 100-mg diclofenac-potassium con-
trolled release (CR) (n = 31) or 50-mg diclofenac-potassium immediate re-
lease (IR) (n = 31) for the relief of pain associated with knee osteoarthritis.
WOMAC Score CR IR
Administration Category Group P* Group P* P†
Baseline Function 29.23 – 27.55 –
Pain 7.30 – 6.74 –
Rigidity 3.13 – 2.42 –
Total 39.70 – 36.71 – 0.649
Day 15 Function 18.07 <0.001 15.55 <0.001
Pain 4.00 <0.001 3.65 <0.001
Rigidity 1.67 <0.001 1.17 <0.001
Total 23.73 <0.001 19.70 <0.001 0.459
Day 30 Function 15.44 0.010 11.75 <0.001
Pain 3.44 <0.001 2.71 <0.001
Rigidity 1.78 <0.001 1.07 <0.001
Total 19.24 <0.001 14.50 <0.001 0.485
*Versus baseline (Wilcoxon signed rank test).
†Between-group comparison. No significant between-group differences were found (Mann-Whitney
rank-sum test).
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pain.28 Therefore, it is vital for the clinician to be able to control the inflamma-
tory process, which will ultimately allow more adequate control of the pain.
Diclofenac-potassium has been widely used on patients suffering from osteo-
arthritis and has been found to be significantly better than acetaminophen in
regard to the symptomatic treatment of this illness.11–14
In this study, 62 patients took diclofenac-potassium in 2 different galenic for-
mulations. In both groups the medication alleviated the pain without difference
in the primary outcome measured with the 100-mm VAS. Similar results were
observed in the WOMAC index scores. When the opinion about changes in pain
between the 2 kinds of medication was evaluated, we observed that signifi-
cantly more patients in the IR group reported a favorable change when com-
pared with the CR group (94% vs 76%, respectively; P = 0.002). However, signifi-
cantly more patients in the IR group used rescue medication than those in the
CR group (36% vs 26%, respectively; P = 0.03). This might explain why this group
experienced a more significant improvement in pain.
In terms of tolerability, both groups finished with a similar profile; no statistically
significant differences were observed. However, taking into account patient with-
drawal due to lack of efficacy, 3 patients in the IR group withdrew from the study,
while only 1 patient from the CR group withdrew for that reason (P = 0.004).
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Figure 2. Progression of mean Western Ontario McMaster (WOMAC) osteoarthritis
index questionnaire scores from treatment initiation to study end in
patients receiving 100-mg diclofenac-potassium controlled release (CR) or
50-mg diclofenac-potassium immediate release (IR) for the relief of pain
associated with knee osteoarthritis.
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The efficacy of diclofenac-potassium IR has been previously demonstrated in
this type of patient, but the new galenic CR formulation had not been previously
tested. Both groups reported improvement in pain and in WOMAC index scores.
However, it must be taken into account that in the CR group, fewer patients used
rescue medication, fewer withdrawals were due to a lack of efficacy, and no pa-
tients withdrew due to AEs.
This study was conducted over the course of 30 days. Future studies should
examine long-term tolerability as the typical patient will receive treatment for
an extended portion of their life. 
CONCLUSION
Based on the results from this small study in a Venezuelan population, both IR
and CR formulations of diclofenac-potassium had similar effectiveness and tol-
erability profiles.
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